TABLE 2.
Efficiency of pCMV/VP1- or VV-VP1-induced protection against normally lethal CVB3 challenge
| Exptl groupa vaccinated with | IgG antibody levels after vaccinationb (ELISA, OD490) | % Survival following CVB3 challenge at indicated day p.i.c
|
|
|---|---|---|---|
| 7 | 28 | ||
| pCMV | 0.17 ± 0.04 | 0 | 0 |
| pCMV/VP1 | 0.30 ± 0.08 | 72.2 | 72.2 |
| VVSC11 | 0.14 ± 0.02 | 0 | 0 |
| VV-VP1 | 0.21 ± 0.02 | 28.6 | 5.6 |
| Nonvaccinated | 0.12 ± 0.02 | 0 | 0 |
BALB/c mice were immunized either with 2 × 200 μg of pCMV/VP1 or with a single dose of 107 PFU of VV-VP1. Control mice remained uninfected, were inoculated with 2 × 200 μg of pCMV, or were infected with 107 PFU of VVSC11.
Four weeks after the last injection, sera were obtained and analyzed for the presence of CVB3-specific antibodies by ELISA. The serum dilution was 1:25. The data are the mean values ± standard deviation. OD490, optical density at 490 nm.
Four weeks after immunization, mice were challenged with 5 LD50s of CVB3 i.p. The percentage of animals surviving is shown at days 7 and 28 after challenge. The results are representative of three different experiments.